Prime_therapeutics Prior Authorization Lookup
Latest Prime_therapeutics prior authorization updates25
- Prior AuthClinical/Medical PolicyEff. 2026-11-15Agamree and Emflaza Prior Authorization with Quantity Limit Program SummaryPrior authorization, renewal, and quantity-limit criteria for Agamree and Emflaza under the Boeing commercial formulary.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-15Antidepressants Step Therapy Program SummaryThis policy governs prior authorization and step therapy approval for targeted antidepressant agents and specified duloxetine products under the Boeing commercial formulary. Coverage generally requires use, inadequate response, intolerance, contraindication, or another documented medical-necessity exception involving generic antidepressant or other prerequisite agents.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-15ApoC3 Targeting Agents Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Tryngolza (olezarsen) and Redemplo (plozasiran) for commercial Boeing members. It establishes initial-therapy, renewal, clinical-criteria, and quantity-limit requirements.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-15Dojolvi (triheptanoin) Prior Authorization Program SummaryThis policy governs prior authorization and renewal approval for Dojolvi 100% oral liquid for commercial plan members. Coverage is evaluated based on the diagnosis or supported indication, specialist involvement, clinical benefit on renewal, contraindications, and specific use limits for LCFAOD.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-15Duvyzat Prior Authorization with Quantity Limit Program SummaryCommercial coverage for Duvyzat 8.86 mg/mL oral suspension under the Boeing prior authorization and quantity limit program, primarily for Duchenne muscular dystrophy.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-15Hyftor Prior Authorization with Quantity Limit Program SummaryThis policy governs commercial coverage for Hyftor 0.2% sirolimus gel for patients with tuberous sclerosis complex and facial angiofibromas. It establishes initial authorization, renewal, specialist, contraindication, and quantity-limit requirements for the Boeing formulary.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-15Isturisa Prior Authorization with Quantity Limit Program SummaryThis policy governs commercial coverage of Isturisa tablets for eligible patients, including initial authorization, renewal, and requests exceeding the program quantity limits. It applies to providers seeking coverage through the Boeing formulary administered by Prime Therapeutics.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-15Xphozah Prior Authorization with Quantity Limit Program SummaryCommercial coverage of Xphozah (tenapanor hydrochloride tablets) for eligible patients through the Boeing client formulary, including prior authorization requirements and quantity limits.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-01Cholestasis Pruritus Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Bylvay, Livmarli, and Lynavoy for qualifying cholestatic pruritus indications under the Boeing commercial formulary.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-01Imcivree Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization, renewal authorization, and quantity-limit exceptions for Imcivree (setmelanotide acetate) 10 mg/mL subcutaneous solution for commercial Boeing members, including approved or supported genetic, syndromic, and acquired hypothalamic obesity indications.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-01Resmetirom Prior Authorization and Quantity LimitsThis policy governs coverage of Rezdiffra (resmetirom) tablets for Boeing commercial members, including initial authorization, renewal, and quantity-limit exceptions. Coverage requires clinical criteria for noncirrhotic NASH/MASH with moderate-to-advanced fibrosis or another FDA-labeled indication, along with applicable safety, specialist, and documentation requirements.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-11-01Rhapsido Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization, renewal, and quantity-limit approval for Rhapsido (remibrutinib) 25 mg tablets under the Boeing commercial formulary. It applies to providers requesting coverage for initial or continued therapy.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-19PCSK9 Inhibitors Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Praluent, Repatha formulations, Lerochol, and Lipfendra for commercial plan members. It establishes covered indications, statin-use or intolerance requirements, preferred-agent rules, continuation criteria, and quantity-limit exceptions.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-15Hypoactive Sexual Desire Disorder (HSDD) Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity limits for Addyi (flibanserin) and Vyleesi (bremelanotide) for hypoactive sexual desire disorder and related female sexual interest/arousal disorder in commercial plan members.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Alternative Dosage Form Prior Authorization with Quantity Limit Program SummaryThis program summary governs prior authorization and quantity limits for selected alternative dosage form prescription drugs, including oral solutions, suspensions, granules, sprinkle capsules, suppositories, nasal sprays, and sublingual tablets, for listed commercial formulary products and associated generic agents.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Cannabidiol Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Epidiolex (cannabidiol oral solution 100 mg/mL) for Boeing commercial members. It establishes initial-therapy, renewal, clinical indication, safety, specialist, and quantity-limit requirements for providers.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Cibinqo Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Cibinqo (abrocitinib tablets) for Boeing commercial members, including initial, continuation, renewal, clinical, safety, specialist, combination-therapy, and quantity-limit requirements.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Endari (glutamine) Prior Authorization Program SummaryThis policy governs prior authorization approval and renewal for Endari (glutamine) 5-gram powder packets for sickle cell disease under the Boeing commercial formulary. It applies to providers requesting initial or continuation therapy.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01HCN Channel Blocker Prior Authorization with Quantity Limit Program SummaryPrior authorization and quantity-limit requirements for Corlanor (ivabradine) oral solution and tablets for Boeing commercial members, including initial and renewal criteria, heart-failure requirements, prescriber qualifications, safety screening, and dose limits.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Healthcare Administered Multiple Sclerosis Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity limits for healthcare-administered multiple sclerosis therapies under the Boeing commercial formulary. It applies to providers requesting Lemtrada, Ocrevus, Ocrevus Zunovo, Tyruko, or Tysabri for eligible members.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01IL-31 Inhibitors Prior Authorization with Quantity Limit Program SummaryPrior authorization, renewal, and quantity-limit requirements for Nemluvio (nemolizumab-ilto) subcutaneous autoinjector therapy under the Boeing commercial formulary, including prurigo nodularis, moderate-to-severe atopic dermatitis, and other supported indications.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Leqembi iqlik Prior Authorization and Quantity LimitsCommercial coverage, prior authorization, and quantity-limit exceptions for Leqembi iqlik autoinjector pens used to treat Alzheimer's disease in Boeing commercial members.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Lupus Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit coverage for Benlysta, Lupkynis, and Saphnelo products used for lupus-related indications in Boeing commercial plans.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Somatostatins Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity limits for selected somatostatin-related drugs and pegvisomant/paltusotine products in the Boeing commercial formulary. It applies to providers requesting initial or renewal coverage for these agents.All prime_therapeutics updates
- Prior AuthClinical/Medical PolicyEff. 2026-10-01Yuviwel Prior Authorization with Quantity Limit Program SummaryThis policy governs prior authorization and quantity-limit approval for Yuviwel (navepegritide) for Boeing commercial members, including initial and renewal criteria, quantity-limit exceptions, required documentation, and a 12-month approval duration.All prime_therapeutics updates
Tool Description
Search Prime_therapeuticsprior authorization policies by drug name, procedure, or policy title. Results include any policy that mentions prior authorization requirements (drug coverage criteria, imaging guidelines, site-of-service rules) not just documents titled “prior authorization.” Every result links to a full policy page with clinical criteria, covered billing codes, documentation requirements, and effective dates.
Filter by payer, specialty, policy type, or effective year; or search directly for a drug (“Wegovy,” “Ozempic”), a procedure (“MRI,” “knee arthroplasty”), or a policy number.
Coverage spans 110+ payers. Jump straight to the busiest prior-auth publishers: UnitedHealthcare, Cigna, Aetna, Anthem, and Centene. You can also browse the full policy updates feed.
Pair a prior-auth search with the billing code lookup to confirm the CPT or J-code on the claim, the payer lookup for plan footprint, and payer profiles for contacts and coverage context.
FAQ
Prior Authorization by Payer
Go deeper
Explore OpenPayer Data
Prior auth requirements change all the time. Keep up with every payer policy update in the live policy feed, or browse payers with prior authorization policies.
Toolbox
More OpenPayer Tools
- Billing Code LookupSearch CPT, HCPCS, J-codes, DRG, and dental codes by number or procedure name.
- Billing Code Reimbursement RatesBuild a reimbursement rate report across any mix of billing codes and states, comparing commercial payers against Medicare.
- Payer Comparison DashboardPick 2-5 payers to compare market share, premium, and membership by region, all at once.
- Facility Comparison DashboardPick 2-6 hospital facility types (or add a specific hospital) to compare facility count, revenue, net income, and Medicare/Medicaid payer mix by region, all at once.
- Healthcare Provider & Facility LookupFind hospitals and healthcare facilities by name, taxonomy, facility type, ownership, or state.
- Health Insurance Payer LookupSearch national health insurance payers and health plans by name and state presence.
- Provider Taxonomy Code LookupSearch NUCC taxonomy codes by code, specialty, grouping, or classification.
- CPT Modifier LookupSearch CPT modifiers by code or name — descriptions, when to use them, and payer policy context.
- Timely Filing LookupFind payer timely filing policies: claim deadlines, corrected claim windows, and appeal timeframes.
- Coverage Criteria LookupSearch payer coverage criteria and medical necessity requirements by drug, procedure, or payer.
- Payer Contact DirectoryClaims, prior authorization, provider services, and appeals contacts for health insurance payers.
Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.